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THE ODP STRATEGIC PLAN FOR FISCAL YEARS 2014–2018
 
STRATEGIC PRIORITY I 
Systematically monitor NIH investments in prevention research and
assess the progress and results of that research. 
STRATEGIC PRIORITY II 
Identify prevention research areas for investment or expanded
effort by the NIH. 
STRATEGIC PRIORITY II I 
Promote the use of the best available methods in prevention
research and support the development of better methods. 
STRATEGIC PRIORITY IV 
Promote collaborative prevention research projects and facilitate
coordination of such projects across the NIH and with other public 
and private entities. 
STRATEGIC PRIORITY V 
Identify and promote the use of evidence-based
interventions and promote the conduct of implementation and
dissemination research in prevention. 
STRATEGIC PRIORITY VI 
Increase the visibility of prevention research at the NIH and across
the country. 
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A MESSAGE FROM THE DIRECTOR
 
In a time with numerous public health challenges such as rising
healthcare costs, an aging population, and increased financial
constraints on the biomedical research community, the ODP needs
to be very focused in its efforts to improve prevention research at
the NIH. To this end, I decided to lead the development of the first
strategic plan for the ODP soon after accepting the position. We
provide the results of that effort in this report. 
The ODP Strategic Plan for Fiscal Years 2014–2018 outlines the
priorities that the Office will focus on over the next 5 years.
A primary function of the ODP is to assist the NIH Institutes
and Centers with the development of new collaborations and
initiatives across the NIH and with other public and private
entities to advance disease prevention research. The ODP relies
on the scientific expertise of NIH Institute and Center staff to
help us gauge the impact of work being done in prevention.
 
This partnership also serves to promote dialogue across disparate areas to identify and address gaps in
 
prevention research. To achieve success, the ODP must enhance existing partnerships and forge new
 
ones as we implement the strategic plan.
 
The six priority areas included in the plan chart new directions for the ODP and, at the same time, build
 
upon and expand established programs. For example, the ODP will develop new processes to better
 
categorize the NIH prevention research portfolio to identify pressing research needs. The ODP will then
 
address those needs through the development of collaborations with NIH Institutes and Centers and other
 
partners. The ODP will create new training programs to educate NIH staff and the extramural community
 
about the best available methods in prevention research to ensure that research programs and projects are
 
managed and developed based on the current state of the science. The ODP will continue to develop its
 
information dissemination efforts to reach a broader audience and to increase the visibility of the results of
 
NIH-supported prevention research.
 
This plan was created using an inclusive process that gathered input from NIH scientific and planning
 
experts, other federal agencies, the extramural research community, professional societies, the healthcare
 
sector, and the patient community, as well as the general public. Their thoughtful comments and
 
suggestions were fundamental in the design and content of the final plan. We are grateful for the support
 
received throughout the development process and look forward to working with our partners as we
 
address our strategic priorities.
 
David M. Murray, Ph.D. 
Associate Director for Prevention 
Director, Office of Disease Prevention, NIH 
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INTRODUCTION TO THE OFFICE OF DISEASE PREVENTION
 
MISSION STATEMENT 
The mission of the ODP is to 
improve the public health by 
increasing the scope, quality, 
dissemination, and impact 
of prevention research 
supported by the NIH. The 
ODP will fulfill this mission by 
providing leadership for the 
development, coordination, 
and implementation of 
prevention research in 
collaboration with NIH 
Institutes and Centers and 
other partners. 
VISION STATEMENT 
By 2018, the ODP will extend 
its value as a resource to 
the NIH and the broader 
prevention research 
community, providing 
guidance in prevention 
research methodology, 
identifying gaps in existing 
evidence and facilitating 
coordination of new 
activities to address those 
gaps, promoting quality 
improvements in the review 
of prevention research, 
and increasing the impact 
and visibility of prevention 
research. 
The National Institutes of Health (NIH) established the
Office of Disease Prevention (ODP) in 1986 in response to
a directive in the Health Research Extension Act to create
the position of NIH Associate Director for Prevention (see
Appendix A: Key Dates in the History of the Office of Disease
Prevention). Among other responsibilities, the Associate
Director was charged with promoting and coordinating
prevention research among NIH Institutes and Centers and
between the NIH and other public and private entities. Today,
the mission of the ODP is to improve the public health by
increasing the scope, quality, dissemination, and impact
of prevention research supported by the NIH. Under the
direction of the Associate Director for Prevention, who is
also the Director of the ODP, the Office fulfills this mission by
providing leadership for the development, coordination, and
implementation of prevention research in collaboration with
NIH Institutes and Centers and other partners. 
The ODP resides in the NIH Office of the Director, Division
of Program Coordination, Planning, and Strategic Initiatives,
which identifies and reports on research on important areas
of emerging scientific opportunities, rising public health
challenges, or knowledge gaps that deserve special emphasis.
In addition to disease prevention, the Division also includes
major programmatic offices that coordinate research and
activities related to AIDS, behavioral and social sciences,
women’s health, and research infrastructure. 
OFFICES, PROGRAMS, AND
PARTNERSHIPS 
The ODP provides overall guidance to NIH Institutes and 
Centers on biomedical and public health programs that seek 
to improve the Nation’s health through research, training, 
knowledge translation, and public education as they relate 
to disease prevention. The Office of Dietary Supplements 
(ODS) was created as an office within the ODP to enhance 
research efforts that determine the benefits and risks of 
dietary supplements. In addition, the ODP collaborates with 
other federal agencies, academic institutions, the private 
sector, and nongovernmental organizations in formulating 
S T R A T E G I C  P L A N  2 0 1 4 – 2 0 1 8 4 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
research initiatives and policies that promote public health. ODP programs and partnerships are divided 
into four main areas of focus: Research Coordination; Evidence Assessment; Training and Education; and 
Communications and Outreach. Examples of these activities are provided below. 
OFFICES 
Office of Dietary Supplements
The Office of Dietary Supplements has been part of the ODP since it was created in 1995. Dietary
supplements can have an impact on the prevention of disease and on the maintenance of health; therefore,
it is important to enhance research efforts to determine the benefits and risks of supplements. The mission
of the ODS is to strengthen knowledge and understanding of dietary supplements by evaluating scientific
information, stimulating and supporting research, disseminating research results, and educating the public
about dietary supplements to foster an enhanced quality of life and health. The ODS allocates the majority
of its resources to co-fund research with NIH Institutes and Centers that investigate the potential roles of
dietary supplements in promoting health and reducing the risk of chronic disease. The ODS also engages
its federal partners in activities to fill essential needs that would not otherwise be addressed. For additional
information about the ODS, including its strategic plan, please visit the ODS website. 
PROGRAMS AND PARTNERSHIPS 
Research Coordination 
Research on disease prevention is an important part of the NIH’s mission. The knowledge gained
from this research leads to stronger clinical practice, health policy, and community health programs.
Prevention research and related activities are performed throughout the NIH and at other federal
agencies. The ODP works to coordinate these activities and foster collaboration in areas of prevention
research that are relevant to multiple disciplines and to both public and private organizations. 
Research Co-Funding 
The ODP provides co-funding for extramural prevention grants, intramural projects, and meetings and 
workshops implemented by NIH Institutes and Centers as well as to other federal agencies and offices. 
Priority is given to those areas where current research is lacking or additional research may be stimulated. 
Priority also is given to projects that address prevention research areas of interest to multiple Institutes 
and Centers and those that focus on health disparities. A list of ODP co-funded projects is available on 
the ODP website. 
NIH Prevention Research Coordinating Committee 
To facilitate the coordination of prevention research across the NIH, the ODP convenes the NIH Prevention
Research Coordinating Committee (PRCC), which serves as a venue for exchanging programmatic and 
scientific information on prevention research of interest to the NIH and its federal partners, and for 
providing advice to the Associate Director for Prevention related to the planning and implementation of 
collaborative activities. Almost all NIH Institutes and Centers and program offices within the NIH Office 
of the Director have a representative on the committee. A number of other U.S. Department of Health
and Human Services (HHS) agencies also are represented, including the Centers for Disease Control
and Prevention (CDC), the Agency for Healthcare Research and Quality (AHRQ), and the HHS Office of
Disease Prevention and Health Promotion (ODPHP). 
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WHAT IS PREVENTION RESEARCH?
 
Under the leadership of the ODP, the NIH Prevention Research Coordinating Committee (PRCC) has
worked to ensure that a definition of prevention research communicates the breadth and depth of
prevention research funded by the NIH while also retaining sufficient specificity to be of practical value. The
PRCC Working Definition of Prevention Research is summarized here: 
Summary of PRCC Working Definition of Prevention Research
Prevention research at the NIH encompasses both primary and secondary prevention. It includes
research designed to promote health; to prevent onset of disease, disorders, conditions, or injuries;
and to detect, and prevent the progression of, asymptomatic disease. Prevention research targets
biology, individual behavior, factors in the social and physical environments, and health services,
and informs and evaluates health-related policies and regulations. Prevention research includes
studies for: 
•	 Identification and assessment of risk and protective factors
•	 Screening and identification of individuals and groups at risk
•	 Development and evaluation of interventions to reduce risk 
•	 Translation, implementation, and dissemination of effective preventive interventions
into practice 
•	 Development of methods to support prevention research. 
Research on disease prevention is an important part of the NIH mission. The Institutes and Centers have
broad portfolios of prevention research and training, as well as programs to disseminate the findings
to scientists, health professionals, and the public. Each Institute and Center has the flexibility to adapt
the PRCC Working Definition of Prevention Research to reflect its mission and the state of the science
of its programs. As the ODP implements its strategic plan and begins to examine specific areas within
the NIH prevention portfolio, the Office will work closely with the PRCC and NIH Institute and Center
representatives to identify a process that enables the ODP to focus its efforts, while encouraging a broad
spectrum of prevention research across the NIH, fostering collaborative efforts, and communicating the
importance of prevention research widely. 
Tobacco Regulatory Science Program 
The Tobacco Regulatory Science Program (TRSP) coordinates the trans-NIH collaborative effort with the 
Food and Drug Administration’s (FDA) Center for Tobacco Products to conduct research to support the
FDA’s regulatory authority over tobacco products. With the passage of the 2009 Family Smoking Prevention
and Tobacco Control Act (Tobacco Control Act), the FDA acquired the authority to regulate the manufacture,
marketing, and distribution of tobacco products to protect public health. Within the framework of the Tobacco
Control Act, the NIH and the FDA formed an interagency partnership to foster tobacco regulatory research.
The NIH has the infrastructure for the solicitation, review, and oversight of research projects, and several NIH
Institutes and Centers have long supported tobacco-related research as part of their missions. The FDA has
expertise in tobacco regulatory science and the authority and resources to support research responsive to the
FDA’s regulatory authority. NIH biomedical, behavioral, and social sciences research supported via funding from
the FDA will provide the scientific evidence needed to better inform the FDA’s regulatory authority. 
5 
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Healthy People 
In partnership with the HHS ODPHP, the ODP
participates in the development of the Healthy People
initiative, a comprehensive set of disease prevention
and health promotion objectives for the Nation to
achieve over the next decade. Launched in 1979
and created by scientists both inside and outside of
the federal government, Healthy People identifies a
wide range of public health priorities and specific,
measurable objectives. A set of Healthy People
objectives, called Leading Health Indicators, has been
selected to communicate high-priority health issues
and actions that can be taken to address them. In
collaboration with the ODPHP and other partner
organizations, the ODP provides advice on numerous
Healthy People activities to ensure that NIH input is
provided. ODP staff members serve on the Healthy
People Federal Interagency Workgroup, the principal
advisory body for the overall development and
implementation of the initiative. 
National Prevention Strategy 
The National Prevention Strategy is a comprehensive plan that was designed to help increase the
number of Americans who are healthy at every stage of life. Initiated in 2010 by the National
Prevention Council in consultation with the public and an Advisory Group of outside experts, the
strategy recognizes that good health comes not just from receiving quality medical care, but from
preventing disease before it starts. Called for by the 2010 Affordable Care Act, the strategy provides
evidence-based recommendations that are fundamental to improving the Nation’s health through the
active engagement of all sectors of society. The ODP represents the NIH on the HHS Intradepartmental
Workgroup. This workgroup is led by the CDC, which coordinates the input of federal agencies on
activities related to the National Prevention Strategy. The ODP is charged with identifying NIH efforts
that support the strategic directions and the priority areas of the strategy. 
As a way to continue this commitment to increase awareness of the value of prevention across multiple 
sectors, the National Prevention Council Action Plan was released in 2012. This action plan highlights the 
important contributions that each member department of the Council is making to ensure the health, 
well-being, and resilience of the American people. This plan demonstrates how these departments are 
implementing prevention efforts, in line with their respective missions, to achieve the goal of the National 
Prevention Strategy. The ODP has helped to coordinate inclusion of NIH programs in the action plan to 
help highlight the role of the research community in improving public health. 
Evidence Assessment 
The ODP works with its partners to provide scientific input on various topics with the goal of sharing 
high-quality, evidence-based information with researchers, healthcare professionals, policymakers, and 
the general public. These ODP-supported programs help to identify scientific or clinical areas that need 
additional research to move the field forward. 
6 
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Pathways to Prevention Program 
The Pathways to Prevention program 
coordinates ODP-sponsored workshops 
of experts to identify research gaps 
in a selected scientific area, identify 
methodological and scientific 
weaknesses, and suggest research 
needs. The program aims to move the 
field forward through an unbiased, 
evidence-based assessment of complex 
issues important to prevention. The 
ODP convenes an independent panel 
to provide balanced, objective, and 
informed attention to the topic. 
The panel examines the results of 
a technical report that summarizes 
the state of the science, provides a 
summary of ongoing research, and assesses future research needs. The panel also considers comments 
from the research community and the public during a 2- to 3-day workshop. After considering the 
information made available through the report and at the meeting, the panel composes and releases 
a report of its findings. The ODP ensures that this report is of high quality and is made available to NIH 
Institutes and Centers, researchers, and the public so that it can be used to plan future research. 
Community Preventive Services Task Force 
The Community Preventive Services Task Force (CPSTF) is an independent, nonfederal panel of prevention 
experts that designs rigorous systematic reviews and considers their findings, and develops public health 
recommendations for the Nation and for the CDC to inform decision-making about policy, practice, and 
research priorities for community preventive services. Recommendations from the CPSTF are published 
in the Community Guide to Preventive Services. The ODP is an official liaison member and works with 
the CDC and CPSTF members to ensure NIH input to the draft reports. ODP staff members serve on, 
or recommend NIH scientists to serve on, systematic review teams and also help to translate CPSTF 
recommendations into action. 
U.S. Preventive Services Task Force 
Coordinated by the AHRQ, the U.S. Preventive Services Task Force (USPSTF) is an independent panel 
of experts that designs and considers findings from systematic evidence reviews of a broad range of 
clinical preventive healthcare services and develops recommendations for primary care clinicians and 
health systems. As the NIH liaison to the USPSTF, the ODP works closely with colleagues at the AHRQ 
and with NIH Institutes and Centers to ensure that NIH scientific input for draft evidence reviews and 
clinical practice guidelines is included in the Guide to Clinical Preventive Services. ODP also disseminates 
information to NIH Institutes and Centers about high-priority evidence gaps for clinical preventive services 
that have been identified by the USPSTF. 
7 
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Training and Education 
The ODP coordinates seminars and workshops where scientists and experts from a variety of disciplines 
are invited to present topics of interest to the NIH community and the public at large. These events are 
designed to educate scientists and the general public about prevention research and allow them to hear 
the latest information on relevant scientific topics. 
Medicine: Mind the Gap 
The Medicine: Mind the Gap seminar series explores a wide range of issues in prevention at the 
intersection of research, evidence, and clinical practice—especially areas in which conventional wisdom 
may be misleading. The seminar series aims to engage the NIH community in thought-provoking 
discussions to challenge what we think we know and to examine today’s research environment. Seminars 
have explored topics such as the gap between ethical theory and medical practice; the role of medical 
evidence in reducing practice variation and controlling costs; approaches for achieving scientific equity 
for the prevention of mental, emotional, and behavioral disorders in minorities and other populations; 
engineer-inspired approaches for optimizing behavioral interventions for increased public health impact; 
and strategies for promoting psychological resilience in the U.S. military. 
Robert S. Gordon, Jr. Lecture in Epidemiology 
The Robert S. Gordon, Jr. Lecture in Epidemiology is part of the NIH’s Wednesday Afternoon Lecture Series,
which invites distinguished scientists to present topics of broad scientific interest to a cross-section of the NIH
community. The ODP established the lectureship in recognition of Dr. Gordon’s outstanding contributions
to the field of epidemiology and for his distinguished service to the NIH. The award is made annually to a
scientist who has contributed significantly to the field of epidemiology or clinical trials research. 
Communications and Outreach 
The communications and outreach program in 
the ODP provides timely, accurate information 
about disease prevention research supported by 
the NIH. Target audiences include the extramural 
research community, national voluntary health 
agencies, health professionals, Congress, the 
media, and the general public. 
The ODP website offers information on all 
aspects of the Office. This website gives the 
ODP an opportunity to inform the public 
about NIH programs, sponsored research, 
and accomplishments, and provides insight 
on key disease prevention topics. The ODP’s 
outreach efforts consist of electronic as well as 
printed materials for both internal and external 
communities and partners about ongoing activities, events, and news. The ODP also has developed and 
implemented a social media plan to increase awareness of the Office and the broader prevention research 
landscape at the NIH. In addition, the ODP works with various media outlets by responding to their 
inquiries and requests for interviews with subject matter experts. 
8 
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THE ODP STRATEGIC PLAN FOR FISCAL YEARS 2014–2018
 
OVERVIEW 
The ODP implemented an extensive and inclusive process to develop a strategic plan that would outline
the priorities for the Office over the next 5 years and highlight the ODP’s role in advancing prevention
research at the NIH (see Appendix B: Strategic Planning Process and Stakeholder Engagement). Feedback
was solicited from multiple stakeholder communities including NIH Institutes and Centers, academia,
industry, healthcare professionals, patient advocates and advocacy organizations, scientific and professional
organizations, federal agencies, and other interested members of the public. Based on this feedback, six
strategic priorities were selected as the framework for the plan. The priorities represent the breadth of ODP
activities and allow for emerging areas of opportunity to be incorporated into Office activities. The priorities
are not mutually exclusive and are not presented in order of importance. It is anticipated that outcomes
associated with each objective will contribute to the overall success of the Office in achieving its vision. 
The ODP Strategic Plan for Fiscal Years 2014–2018 represents an important shift in the core functions of the
Office. Building upon expertise in areas such as program coordination and partnership development, the
ODP will expand its reach by, for example, providing training in prevention methodology and developing
new strategies for identifying research needs. Interest in disease prevention has grown, and the NIH has a
responsibility to ensure that the best prevention science is supported to inform clinical and public health
initiatives at the individual, organizational, community, and policy levels. The strategic priorities included in
the plan will allow the ODP to play an important role in that process. 
STRATEGIC PRIORITIES FOR FISCAL YEARS 2014–2018
 
I. Systematically monitor NIH investments in prevention research and assess the progress and results of
that research. 
II. Identify prevention research areas for investment or expanded effort by the NIH. 
III. Promote the use of the best available methods in prevention research and support the development of
better methods. 
IV. Promote collaborative prevention research projects and facilitate coordination of such projects across the
NIH and with other public and private entities. 
V. Identify and promote the use of evidence-based interventions and promote the conduct of implementation
and dissemination research in prevention. 
VI. Increase the visibility of prevention research at the NIH and across the country. 
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PRIORITY I 
Characterize
Research 
Portfolio 
PRIORITY II 
PRIORITY IIIPRIORITY IV 
PRIORITY V 
Identify 
Research 
Gaps 
Improve 
Research
Methods 
Promote 
Collaborative 
Research 
Promote and Use
Evidence-Based
Interventions PRIORITY VI 
Communicate
Efforts and
Findings 
As the ODP engaged its stakeholders and gathered input on pressing needs in biomedical research and
public health, several themes emerged. For example, the ODP was encouraged to continue to promote
a research agenda at the NIH that addresses the increasing health needs evident in a diverse range of
subpopulations that include individuals from various racial/ethnic, gender, age, socioeconomic, education,
disability, and geographic groups. The ODP will work with stakeholders to include the needs of these
communities in the activities outlined in the strategic plan in order to identify and better understand the
factors that contribute to health disparities; improve the development, dissemination, and implementation
of culturally appropriate prevention interventions; and enhance training opportunities for researchers
examining these disparities. 
Another theme that emerged from discussions with stakeholders is the need to improve the promotion
and dissemination of the results of NIH prevention research. As a program coordination office within the
NIH Office of the Director, the ODP has the flexibility to deliver prevention messages that address a variety
of diseases, disorders, conditions, and injuries that are relevant to multiple audiences (e.g., children, elderly,
minority communities). In addition, the ODP will strive to become a central portal within the NIH for
prevention researchers by providing information that will help scientists navigate the grant application and
review processes as well as gain insight into the best methods for measurement, study design, intervention,
evaluation, and analysis. 
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STRATEGIC PRIORITY I 
Systematically monitor NIH investments in
prevention research and assess the progress and
results of that research. 
BACKGROUND 
The ODP can play an important role in characterizing
the portfolio of prevention research funded by the
NIH. Currently, NIH prevention research is identified
based on a broad definition of prevention that does
not provide sufficient detail to classify studies into
categories of interest. New methods are needed
that identify characteristics of studies—such as
topic area, study design, population studied—and
summarize the findings in a meaningful way for
program planning and reporting. This more specific
characterization of the prevention research portfolio,
along with portfolio analysis tools, would enable identification of patterns and trends, as well as research
areas that may benefit from targeted efforts by the NIH Institutes and Centers. Such categorization also
would enable assessment of the progress and changes in prevention research over time. 
OBJECTIVES 
The objectives supporting Strategic Priority I focus on the development of a taxonomy for prevention
research that can be used to analyze the broader NIH portfolio. The ODP also will ensure that this
process appropriately aligns with other efforts at the NIH, such as the Research, Condition, and Disease
Categorization process. Furthermore, the ODP will work closely with colleagues in the NIH Office of
Portfolio Analysis to apply existing approaches and develop new tools to improve our understanding of NIH
prevention research investments. Using these tools, the ODP will perform portfolio analyses to characterize
the NIH prevention research portfolio and develop products (e.g., reports) that can be shared with
collaborators within and outside of the NIH. The ODP will examine historical and prospective information
using the new portfolio analysis tools to analyze the progress of NIH prevention research. 
OBJECTIVE I.1: Establish a taxonomy for prevention research that ODP can apply to analyze the
NIH prevention research portfolio. 
OBJECTIVE I.2: Develop, test, and implement portfolio analysis tools to classify NIH awards
based on the taxonomy for prevention research. 
OBJECTIVE I.3: Develop and implement a process to regularly assess the progress and results of
NIH investments in prevention research. 
11 
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SPOTLIGHT ON RESEARCH:
Categories of Prevention
Different organizations and research communities classify prevention activities in different ways. Many 
experts distinguish primary and secondary prevention activities based on whether they target individuals 
without the health condition of interest (primary prevention) or whether they target individuals with the 
health condition of interest (secondary prevention). Beyond that distinction, there is no agreement on 
what activities are included as either primary or secondary prevention. For the ODP strategic plan and 
related activities, the ODP will define primary and secondary prevention as follows: 
Primary prevention is the prevention of a new health 
condition, such as a disease, disorder, or injury. This can 
be done through a variety of approaches, including health 
promotion programs aimed at improving diet and exercise 
and reducing obesity and tobacco use; immunization 
programs; environmental health programs to ensure a safe 
water supply or reduce exposure to agricultural chemicals 
and other harmful agents in the environment; and policies 
designed to require seat belt use. Such programs target 
at-risk populations or the general population. The key 
feature is that they are designed to prevent the development 
of a health condition in individuals who do not have it 
yet. Primary prevention also includes identification and 
assessment of risk and protective factors for onset of a new 
health condition. 
Secondary prevention is the early detection and treatment of 
an asymptomatic or early-stage health condition to prevent 
or slow the progression to a more serious condition or the 
prevention of the recurrence of a health condition. Examples include screening for glaucoma, breast 
cancer, depression, or coronary artery disease and the early treatment of these problems before they 
progress, or prevention of a second stroke or heart attack in patients who have had a first stroke or heart 
attack. Secondary prevention also includes identification and assessment of risk and protective factors for 
recurrence of a health condition. 
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STRATEGIC PRIORITY II 
Identify prevention research areas for investment
or expanded effort by the NIH. 
BACKGROUND 
The ODP can assist NIH Institutes and Centers by identifying
prevention research needs and gaps, and prioritizing them on
an ongoing basis. In this process, ODP should make use of the
variety of prevention research data sources available, including,
but not limited to, NIH portfolio analysis and reports from
other federal agencies and task forces. Regular engagement
with stakeholders such as the U.S. Preventive Services Task
Force (USPSTF), the Community Preventive Services Task Force
(CPSTF), and the extramural prevention research community
also will inform the identification of prevention research areas
for investment or expanded effort by the NIH. In addition, the
ODP will work closely with colleagues at the NIH to promote
a research agenda that examines a variety of issues including
health disparities and social determinants of health, as well as
the role of the environment in disease prevention, and improves
health across the life course.
OBJECTIVES 
The objectives supporting Strategic Priority II include working with stakeholders to identify needs for
prevention research, a comparison of those needs with the current NIH portfolio, and collaboration with
the NIH Institutes and Centers to prioritize gaps in prevention research for additional investment. Results
of these efforts will be compiled and shared with others at the NIH to identify areas that warrant further
study; the ODP also will use these results to guide its own co-funding decisions. Strategic Priority II relies
on building collaborations between the ODP and NIH Institutes and Centers, federal agencies, nonfederal
task forces and other organizations that routinely conduct systematic evidence reviews (e.g., USPSTF,
CPSTF, Cochrane Collaborative, Institute of Medicine), existing evidence-based public health initiatives (e.g.,
Healthy People), and other stakeholders to identify, promote, and address needs in prevention research. 
OBJECTIVE II.1: Work with stakeholders to identify needs in prevention research. 
OBJECTIVE II.2: Compare those needs with the current NIH portfolio to identify gaps in
prevention research (i.e., those areas that are not being addressed or have insufficient funding). 
OBJECTIVE II.3: Work with the NIH Institutes and Centers to prioritize the prevention research
gaps for investment or expanded effort. 
1 3  
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SPOTLIGHT ON RESEARCH:
Addressing Needs in the Prevention of HIV/AIDS
Kaplan-Meier estimates for the cumulative probabilities
of linked HIV-1 transmission between partners in the
early-therapy and delayed-therapy groups (Figure 2:
Panel A, Cohen et al., 20111). 
The NIH is committed to the research necessary
to successfully end the HIV/AIDS pandemic.
Each year, 50,000 people in the United States
become infected with HIV, the virus that causes
AIDS. Currently, there are an estimated 1.1
million people in the United States and 34
million people globally who are living with HIV
infection. In 2011, 1.7 million people died from
AIDS-related causes. From the laboratories
and clinics at the NIH to the vast network of
NIH-supported research at universities, medical
centers, and clinical trial sites around the globe,
the NIH is working to better understand HIV
and how it causes disease, find new tools to
prevent HIV infection, develop new and more
effective treatments for HIV-infected people,
and find a cure. 
Under the leadership of the National Institute
of Allergy and Infectious Diseases and the
Office of AIDS Research, the NIH is conducting and supporting research to develop new strategies to 
prevent the spread of HIV. NIH-supported researchers have shown that the use of early versus delayed 
antiretroviral therapy in newly infected individuals can reduce the risk of the sexual transmission of 
HIV by 96%.1
1 
2 
Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. New Engl J Med. 2011;
365:493–505. http://www.ncbi.nlm.nih.gov/pubmed/21767103. Accessed August 23, 2013. 
 Similarly, NIH-supported research has shown that pre-exposure prophylaxis, the use of 
antiretrovirals by uninfected individuals who are at high risk of HIV infection, can also decrease HIV 
infection.2
Grant RM, Lama JR, Anderson PL, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
New Engl J Med. 2010;363:2587–2599. http://www.ncbi.nlm.nih.gov/pubmed/21091279. Accessed September 24, 2013. 
 Other NIH research is examining the use of topical microbicides, such as gels, creams, and 
foams, that can be applied prior to sexual intercourse. The NIH is committed to finding scientifically 
proven HIV prevention strategies and methods that are acceptable for use by different patient 
populations around the world to combat the HIV/AIDS pandemic, including an HIV vaccine. 
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STRATEGIC PRIORITY II I 
Promote the use of the best available methods
in prevention research and support the
development of better methods. 
BACKGROUND 
The best available methods in prevention research should be utilized to move the state of the science
forward. Increased awareness of and training in the use of newer and more efficient approaches for research
design, intervention development, measurement, and analysis are needed to improve both the quality
and success of prevention research applications submitted to the NIH. Opportunities exist for the ODP to
support the development of these methods and to encourage training in their use for a variety of audiences,
including NIH program and review staff, intramural investigators, and the extramural community. 
OBJECTIVES 
The objectives supporting Strategic Priority III include the 
development of a compendium of prevention science tools 
that focus on methods, measures, and analytic techniques. 
The ODP will identify training opportunities for NIH program 
and review staff and extramural investigators on methods 
research to foster better informed decisions and higher 
quality science in prevention research. The ODP will work 
with federal agencies that have interests in prevention 
science methods to share resources and materials. The ODP 
will work with the NIH Center for Scientific Review to identify experts in prevention science methods who 
could serve on NIH study sections. In collaboration with NIH Institutes and Centers, the ODP will develop 
Funding Opportunity Announcements to promote innovative research designs, new tools, and analytic 
techniques to help move the field of prevention science forward. The ODP also will work with experts in 
the field of methodology to identify and build consensus around best practices in prevention science. 
OBJECTIVE III.1: Develop a list of existing NIH and other federal resources pertaining to
prevention science methodology. 
OBJECTIVE III.2: Provide training in prevention science methods to NIH program and review
staff and to extramural investigators. 
OBJECTIVE III.3: Develop NIH Funding Opportunity Announcements that encourage innovative
and improved approaches to prevention science. 
OBJECTIVE III.4: Work with stakeholders to identify and disseminate “best practices” in
prevention science methods. 
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SPOTLIGHT ON RESEARCH:

Designing Informative Studies 
Prevention research requires scientific methods
suited to addressing questions about preventing
disease and deriving answers that can be applied
in clinics, communities, and broader environments.
Prevention research often examines factors that
increase the likelihood of future disease, such
as level of blood pressure or amount of body
weight. Research also needs to assess “upstream”
influences, such as effects of environmental and
societal factors on health behaviors and on health.
Influences on disease onset are part of a complex
system of multiple factors, from individuals’
knowledge and behaviors, environmental
exposures, social determinants, clinical care
practices, and community policies. 
Some scientific advances have been made to address these issues. Methods have been developed for
conducting group-randomized trials, where an entire existing group of individuals is randomly assigned to
receive an intervention or not—groups such as schools, healthcare sites, worksites, or entire communities— 
so that the results are directly relevant to practice because the research is done in “the real world.” To
assess continuous outcomes such as blood pressure level, methods have been developed that enable
researchers to “impute” or assign values to those study participants for whom data are missing, which leads
to more accurate conclusions. Complex system modeling has been developed to take into account multiple
simultaneous factors that may affect outcomes, and to vary aspects of the system to examine downstream
effects on health outcomes. These are just a few examples where advances in methodology and study
design have been achieved. However, the development of new or improved methodological approaches is
warranted, as well as training in how to apply these methods. 
There is ample evidence that better training for investigators, program staff, review staff, and reviewers is
needed. Consider, as an example, a recent review of group-randomized trials involving cancer and cancer
risk factors. Murray et al. (2008) found 75 studies published across 41 peer-reviewed journals between
2002 and 2006.3
3 Murray DM, Pals SL, Blitstein JL, et al. Design and analysis of group-randomized trials in cancer: a review of current practices. J Natl
Cancer Inst. 2008 Apr;100(7):483–491. http://www.ncbi.nlm.nih.gov/pubmed/18364501. Accessed August 24, 2013. 
 Only 45% reported analyses that were entirely appropriate (all analyses were valid for
the design employed). This pattern held even for studies reviewed by NIH study sections and funded by
NIH Institutes and Centers. As the authors noted, “A collaborative effort by investigators, statisticians, and
others will be required to ensure that group-randomized trials are planned and analyzed using appropriate
methods so that the scientific community can have confidence in the published results.” 
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STRATEGIC PRIORITY IV 
Promote collaborative prevention research projects
and facilitate coordination of such projects across 
the NIH and with other public and private entities. 
BACKGROUND 
All of the NIH Institutes and Centers support prevention research in their own areas, which has helped
to create a robust and diverse research portfolio that addresses a range of important scientific questions.
Even so, enhanced collaboration and coordination among NIH Institutes and Centers, as well as with
other research partners, could result in better outcomes and more efficient use of resources. The ODP
will encourage coordination of prevention research across the NIH, throughout government, and with
the private sector to identify common or cross-cutting topic areas and research questions, create an
environment of collaboration, and improve complementary and collaborative efforts to enhance the return
on investment for prevention research at the NIH. Collaborations can engage a range of public or private
stakeholder organizations in identifying and working on research priorities. 
OBJECTIVES 
The objectives supporting Strategic Priority IV will
set the stage for collaborative research efforts
in prevention research within the NIH, across
government entities, and with the private sector.
Examples of successful research collaborations
will be sought and used as models for future
efforts. Existing collaborative relationships will be
continued or expanded, and new relationships
will be forged with public and private entities that
can partner on prevention research efforts. These
activities will lead to a coordinated development
of funding opportunities in partnership with NIH
Institutes and Centers as well as with other organizations, which will strengthen the prevention research
portfolio to advance scientific knowledge in order to improve public health. 
OBJECTIVE IV.1: Identify, document, and share best practices for research collaborations within
the NIH and with other stakeholders. 
OBJECTIVE IV.2: Establish or promote infrastructures and processes to foster research
coordination and collaboration across the NIH and with other public and private entities. 
OBJECTIVE IV.3: Coordinate NIH Funding Opportunity Announcements to address areas of
need in prevention research. 
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SPOTLIGHT ON RESEARCH:
NIH-FDA Tobacco Regulatory Science Program 
Tobacco use is the single most preventable cause of death and disease in the United States. Each year,
approximately 443,000 Americans die from tobacco-related illnesses. For every person who dies from
tobacco use, 20 more people suffer with at least 1 serious tobacco-related illness. In addition, tobacco
use costs the United States $193 billion annually in direct medical expenses and lost productivity. With
the historic passage of the 2009 Family Smoking Prevention and Tobacco Control Act (Tobacco Control
Act), the FDA acquired the authority to regulate the manufacture, marketing, and distribution of tobacco
products to protect public health. The FDA established the Center for Tobacco Products (CTP) to oversee
the implementation of the majority of
the Tobacco Control Act and formed an
interagency partnership with the NIH
to develop the research base needed to
inform the FDA’s regulatory authority. As
a result, the Tobacco Regulatory Science
Program (TRSP) was created within the
ODP to collaborate with the CTP and
coordinate tobacco regulatory science
across NIH Institutes and Centers. 
Although a substantial science base
exists with regard to numerous areas
of the Tobacco Control Act, additional
research is needed to provide scientific
evidence in several key areas. The
TRSP combines the experience and
infrastructure of the NIH with the tobacco regulatory science expertise of the FDA to address areas such as how
to reduce addiction to tobacco products, the adverse health consequences of tobacco use, and how economics
and policies affect tobacco product use. A full list of funded projects is available on the TRSP website. 
Highlights of projects underway include: 
• The Tobacco Centers of Regulatory Science to conduct programs of multidisciplinary research to inform
tobacco product regulation and address research priorities related to the FDA’s regulatory authority.
(Multiple NIH Institutes and Centers)
• Innovative research on how altering nicotine levels in tobacco products could affect the way people
might use tobacco products and become addicted. (National Institute on Drug Abuse)
• Expanding the content of the consensus measures for the Phenotypes and eXposures (PhenX) Toolkit
to establish high-quality, standard measures in support of tobacco regulatory science. (National Human
Genome Research Institute)
• Career Development Awards to provide support and protected time to scientists interested in pursuing
tobacco regulatory research. (Multiple NIH Institutes and Centers)
T H E  O F F I C E  O F  D I S E A S E  P R E V E N T I O N 
  
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
  
STRATEGIC PRIORITY V 
Identify and promote the use of evidence-based
interventions and promote the conduct of
implementation and dissemination research in 
prevention. 
BACKGROUND 
Part of the mission of the ODP is to disseminate the results of high-quality, evidence-based disease
prevention research; foster the use of evidence-based interventions in practice; and promote the further
development of implementation and dissemination research in prevention. Opportunities exist for the ODP
to facilitate these important activities. To expedite the identification and use of evidence-based prevention
interventions, the ODP will collaborate with multiple partners and audiences, including NIH Institutes and
Centers, service providers, and community organizations, to promote the dissemination of evidence-based
disease prevention strategies and interventions with the potential to impact public health. 
OBJECTIVES 
The objectives supporting Strategic Priority V will focus on the development of a web-based portal that
provides access to evidence-based resources and best practices organized by different categories such as
the patient population studied and research design. To ensure that credible information is provided, studies
included must have undergone an independent systematic review by a credible government or private-
sector agency. The ODP will work with stakeholders to promote the dissemination of best practices at the
individual, organizational, community, and policy levels. To facilitate this process, the ODP will develop
messages for stakeholders to use when communicating with various audiences about best practice models
and effective interventions. The ODP also will work with NIH Institutes and Centers to develop strategies to
promote implementation and dissemination research that examines both intervention-level features (e.g.,
core components, recruitment and retention strategies, training and implementation manuals/products,
adaptation guides) and healthcare and community systems-level features (e.g., decision-making, selection,
adoption, adaptation, management, financing, sustainability planning). 
OBJECTIVE V.1: Identify evidence-based interventions for disease prevention and present them
in an organized structure. 
OBJECTIVE V.2: Enhance partnerships to promote the dissemination of evidence-based
interventions for disease prevention. 
OBJECTIVE V.3: Enhance partnerships to promote research on dissemination and
 
implementation of evidence-based interventions in prevention.
 
1 9  
S T R A T E G I C  P L A N  2 0 1 4 – 2 0 1 8 20 
 
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
SPOTLIGHT ON RESEARCH:
Building and Using the Evidence Base 
In the 1950s, the death rates for cardiovascular diseases (CVD)—heart attacks and strokes—had been
climbing in the United States for several decades. The National Heart Institute, which later became the
National Heart, Lung, and Blood Institute (NHLBI), was created to study this epidemic of CVD. The first study
was the Framingham Heart Study, which followed about 5,000 healthy adults over several decades to identify
characteristics associated with subsequent CVD events.4
4 
5 
6 
7 
Sykowski PA, Kannel WG, D’Agostino RB. Changes in risk factors and the decline in mortality from cardiovascular disease. The Framingham
Heart Study. N Engl J Med. 1990;322:1635–1541. http://www.ncbi.nlm.nih.gov/pubmed/2288563. Accessed August 27, 2013. 
 The researchers found that adults with elevated blood
pressure developed cardiovascular events at a higher rate than those without elevated blood pressure. In the
1970s, the evidence was sufficiently strong to launch studies to determine whether reducing elevated blood
pressure would reduce the rate of strokes and other adverse outcomes. One example is the Hypertension
Detection and Follow-up Program, published in the late 1970s, which found that reducing blood pressure
levels reduced stroke and mortality, even in people with “mild” hypertension.5 
Hypertension Detection and Follow-up Program Cooperative Group. Five-year findings of the hypertension detection and follow-up
program. I. Reduction in mortality of persons with high blood pressure, including mild hypertension. JAMA. 7:2562–2571.
http://www.ncbi.nlm.nih.gov/pubmed/490882. Accessed August 27, 2013. 
Age-Adjusted Death Rates for Coronary Heart Disease, Vital
Statistics of the United States, Centers for Disease Control
and Prevention/National Center for Health Statistics. 
This accumulating evidence was sufficient for
the NHLBI to sponsor the National High Blood
Pressure Education Program in the mid-1970s,
which released the first clinical guidelines on
reducing elevated blood pressure, then called
“hypertension.”6
Roccella EJ, Ward GW. The National High Blood Pressure Education Program: a description of its utility as a generic program model.
Health Educ Behav. 1984:11:225–242. http://www.ncbi.nlm.nih.gov/pubmed/6520004. Accessed August 27, 2013. 
 When the findings showed
that a reduction in hypertension reduced
adverse cardiovascular outcomes, studies
were funded to test approaches other than
medications to lower blood pressure, including
exercise and diet. The Dietary Approaches
to Stop Hypertension (DASH) studies found
that a dietary pattern that emphasized fruits,
vegetables, whole grains, fat-free or low-fat
dairy, and lean protein foods that limited
sodium, added sugars, and red meats reduced
blood pressure within 2 weeks without
medication in people with prehypertension and stage 1 hypertension.7
Appel L, Moore T, Obarzanek E, et al. A clinical trial of the effects of dietary patterns on blood pressure. N Engl J Med. 97;336:1117– 
1124. http://www.ncbi.nlm.nih.gov/pubmed/9099655. Accessed August 27, 2013. 
 These results were included in the next
set of clinical guidelines for hypertension treatment. As a result of this translation of research into practice, along
with other evidence-based improvements in prevention such as reducing blood cholesterol with exercise, diet,
and medications, mortality rates for CVD in the Nation declined some 40% over a period of several decades. 
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STRATEGIC PRIORITY VI
 
Increase the visibility of prevention research at
the NIH and across the country. 
BACKGROUND 
The ODP will play a central role in
disseminating information to broaden the
scientific and public health impact of the
NIH prevention research portfolio. The
ODP can enhance prevention research by
disseminating NIH prevention research
and resources, strengthening partnerships
to improve information dissemination,
and gathering input and feedback from
stakeholders including researchers,
program and policy stakeholders, and the
general public. 
OBJECTIVES 
The objectives supporting Strategic Priority VI include the development of resources for the research
community, the public, and other stakeholders. For example, the ODP will expand its website content
by posting a list of NIH staff engaged in prevention research activities to promote networking and
collaboration; explore the use of social media tools such as Facebook and blogs; create an e-newsletter
about NIH prevention research activities and accomplishments; and optimize its website for mobile use
to increase accessibility by stakeholders anywhere, anytime, and on any device. In addition, the ODP
will promote the outcomes of all of its strategic planning efforts to ensure results reach the intended
audiences. The ODP also will identify and develop a stakeholder community that includes the NIH, the HHS,
and other public and private organizations and work with that community to advance communications,
collaborations, and other actions to help disseminate information about prevention research. 
OBJECTIVE VI.1: Increase the availability of information about prevention research through
the use of traditional and digital communication tools. 
OBJECTIVE VI.2: Increase communications and collaborations with stakeholders to
coordinate communications about disease prevention. 
OBJECTIVE VI.3: Support Strategic Priorities I–V via the ODP website and other communication
tools. 
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SPOTLIGHT ON RESEARCH: 
Spreading the Word About Prevention 
The dissemination of the results of the NIH’s investment in prevention research is vital to facilitating research, 
informing health professionals about the latest research findings, and providing the public with science-
based information to help individuals make informed health decisions. The process of getting information 
out to the public has changed dramatically in the last decade. Traditional modes of communication such 
as printed pamphlets and brochures are being replaced by digital communication tools. Technologies such 
as interactive websites and mobile technology allow for increased outreach to a larger audience. Podcasts 
and webinars can be used to provide training and promote knowledge-sharing between people, regardless 
of their location. Social media tools such as Facebook, Twitter, and Tumblr present an opportunity to share 
information and connect with a vast audience instantaneously. 
Prevention is important at every life stage; however, targeting children and teens can be especially 
beneficial. Children and teens are savvy at finding information via digital communication tools and using 
social media; therefore, getting appropriate prevention resources to them as soon as possible provides 
professionals with the opportunity to educate children before negative habits might form. There are many 
ways to deliver evidence-based prevention messages. Below are a few examples from across the NIH: 
Smokefree Teen – A website developed specifically to help teen smokers quit, offers 
tailored information, several social media pages to connect teens with cessation tools, a free 
smartphone application, and text message program. (National Cancer Institute) 
THE SCIENCE 
BEHIND DRUG ABUSE 
NIDA for Teens – This website offers a variety of resources, including a blog for teens,
Drug Facts: Real Questions From Real Teens, links to the National Drug Facts Week site, as
well as information for educators and parents. It also includes the popular PEERx section,
an educational initiative to discourage abuse of prescription drugs, including interactive
Choose Your Path videos that prompt teens to make decisions about everyday dilemmas.
(National Institute on Drug Abuse) 
We Can! (Ways to Enhance Children’s Activity & Nutrition)® – A national education program 
designed to help keep all kids at a healthy weight. It provides resources and community-
based programs for parents, caregivers, and youth that focus on behaviors to encourage 
healthy eating, increase physical activity, and reduce time sitting in front of the screen 
(TV or computer). (National Heart, Lung, and Blood Institute, Eunice Kennedy Shriver 
National Institute of Child Health and Human Development, National Institute of Diabetes 
and Digestive and Kidney Diseases, National Cancer Institute) 
Kids’ Pages – An educational website designed to teach children about the connections
between their health and the environment. A variety of fun, age-appropriate tools are
used to educate kids about how to prevent disease and improve human health by using
environmental sciences to understand human biology and human disease.
(National Institute on Environmental Health Sciences) 
® 
It’s a Noisy Planet. Protect Their Hearing® – A national public education campaign designed
to increase awareness among children ages 8 to 12 and their parents about noise-induced
hearing loss and how to prevent it. The TweenZone highlights when and how to protect your
ears, with interactive content such as a Sound Ruler, quizzes, and a crossword puzzle, plus
educational and fun videos. (National Institute on Deafness and Other Communication Disorders) 
 It’s a Noisy Planet. Protect Their Hearing® logo is a registered trademark of the U.S. Department of Health and Human Services. 
We Can® logo is a registered trademark of the U.S. Department of Health and Human Services. 
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APPENDIX A: KEY DATES IN THE HISTORY OF THE 
OFFICE OF DISEASE PREVENTION
1985–1986
The Office of Disease Prevention (ODP) was created in 1986 in response to a directive in the Health Research 
Extension Act of 1985 to create the position of National Institutes of Health (NIH) Associate Director for 
Prevention. The Associate Director was charged with promoting and coordinating prevention research among 
the NIH Institutes and Centers and between them and other public and private entities. The ODP’s functional 
statement included advising the NIH Director and senior staff; coordinating disease prevention and nutrition 
research activities; and conducting evidence-based assessments of the state of the science and medical practice.
The Office of Medical Applications of Research (OMAR), established in 1977, was transferred from the 
Office of the Director (OD) to the ODP in 1986. OMAR activities included coordinating, reviewing, and 
facilitating the systematic identification and evaluation of clinically relevant information and promoting 
the effective transfer of this information to a variety of stakeholders. A key program in the OMAR 
was the Consensus Development Program (CDP), which held conferences and produced consensus 
statements on important and controversial topics in medicine. Each CDP conference was jointly 
sponsored and administered by one or more Institute, Center, or Office of the NIH and by the ODP.
The Prevention Research Coordinating Committee (PRCC), established in 1980, was transferred from 
the OD to the ODP in 1986. The PRCC serves as an advisory body to the Director of the ODP and makes 
recommendations regarding scientific, programmatic, and policy issues. The PRCC is composed of 
representatives from each of the Institutes and Centers with a disease prevention research portfolio, 
together with representatives from several federal partners with a strong interest in prevention (e.g., 
Centers for Disease Control and Prevention, U.S. Department of Health and Human Services Office of 
Disease Prevention and Health Promotion, Agency for Healthcare Research and Quality).
1995
In 1995, the Office of Dietary Supplements (ODS) was established within the ODP in response to a 
directive in the Dietary Supplement Health and Education Act of 1994. The ODS was charged with 
conducting and coordinating research at the NIH related to dietary supplements; collecting scientific 
data and compiling a database of research on dietary supplements; and serving as a principal advisor on 
dietary supplements to the Assistant Secretary for Health, the Directors of the NIH and the Centers for 
Disease Control and Prevention, and the Administrator of the Food and Drug Administration (FDA).
The Robert S. Gordon, Jr. Lecture also was established in 1995. The award is made annually to a scientist 
who has contributed significantly to the field of epidemiology or clinical trials research. The Gordon 
Lecture is part of the NIH Wednesday Afternoon Lecture Series, which is organized by the Office of 
Intramural Research to invite distinguished scientists to present topics of broad scientific interest to a 
cross-section of NIH researchers.
2003
In 2003, the ODP developed Medicine in the Media, an annual course designed to help develop 
journalists’ and editors’ abilities to evaluate and report on medical research. The course addressed the 
challenges and opportunities inherent in the process of communicating the results of medical research to 
the public. The Medicine in the Media course was sponsored by the ODP, The Center for Medicine and 
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the Media at the Dartmouth Institute for Health Policy and Clinical Practice, Dartmouth Medical School, 
and the U.S. Department of Veterans Affairs’ VA Outcomes Group. Additional support was provided by 
the NIH Office of Communications and Public Liaison.
2007
The ODP established the Medicine: Mind the Gap seminar series in 2007. The series explores issues at 
the intersection of research, evidence, and clinical practice—areas in which conventional wisdom may 
be contradicted by recent evidence. From the role of advocacy organizations in medical research and 
policy, to off-label drug use, to the effectiveness of continuing medical education, the seminar series 
aims to engage the NIH community in thought-provoking discussions that challenge current beliefs and 
encourage critical thinking about today’s research environment, and how the research can be used to 
improve delivery of preventive care.
2008
In 2008, the Division of Program Coordination, Planning, and Strategic Initiatives was established by 
the NIH Reform Act of 2006 to create a Division within the Office of the Director to focus on trans-NIH 
coordination, planning, and strategic initiatives. The ODP, the Office of AIDS Research, the Office for 
Research on Women’s Health, and the Office of Behavioral and Social Sciences joined with several other 
newly created offices to form this new Division within the Office of the Director.
2012
As part of the ODP’s reorganization, OMAR activities, staff, and resources were transferred to the ODP, 
its parent office. The CDP State-of-the-Science Conferences were discontinued, and the program’s focus 
shifted to yearly Consensus Development Conferences on prevention topics with clinical and broad public 
health importance.
The Tobacco Regulatory Science Program (TRSP) was transferred to the ODP in 2012. The TRSP is a trans-
NIH collaborative effort with the FDA’s Center for Tobacco Products to conduct research to support the 
FDA’s regulatory authority for tobacco products.
In 2012, the ODP hosted its first Pathways to Prevention Workshop. These workshops are designed to 
identify methodological and scientific weaknesses in a scientific area and move the field forward through 
an unbiased and evidence-based assessment of a complex issue.
2013
Based in part on the development of the ODP Strategic Plan, the ODP discontinued two of its longstanding 
programs, the CDP, created in 1977, and the Medicine in the Media course, first offered in 2003.
2014
In 2014, ODP released its first strategic plan, for fiscal years 2014–2018.
ASSOCIATE DIRECTORS FOR PREVENTION AND DIRECTORS OF THE OFFICE OF 
DISEASE PREVENTION
William T. Friedewald, M.D. (1986–1989) 
John H. Ferguson, M.D. (Acting, 1989–1991) 
William R. Harlan, M.D. (1991–2001)
Barnett S. Kramer, M.D., M.P.H. (2001–2010)
Paul M. Coates, Ph.D. (Acting, 2010–2012) 
David M. Murray, Ph.D. (2012–Present)
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APPENDIX B: STRATEGIC PLANNING PROCESS AND
STAKEHOLDER ENGAGEMENT 
Prior to engaging stakeholders, the Office of Disease Prevention (ODP) prepared draft mission and vision 
statements and a set of strategic priorities. The Office also outlined the proposed planning process, 
including a stakeholder engagement strategy. This information was shared with the National Institutes of 
Health (NIH) leadership, and revisions to the materials were completed. Once final approval was received, 
the ODP implemented its planning process which included the activities mentioned below. 
An initial step in the planning process was the recruitment of a Working Group composed of NIH 
scientific program and strategic planning experts, as well as representatives from other federal agencies, 
the extramural research community, the healthcare sector, and the public. The Strategic Planning Working 
Group was charged with the following: 
•	 Making recommendations on the scope of the plan and the planning timeline. 
•	 Reviewing and providing advice on mission and vision statements and strategic priorities. 
•	 Reviewing and providing advice on the objectives, measures, and tactics identified to implement the plan. 
•	 Providing advice on key stakeholder groups, informing the selection of questions for each
stakeholder group, and recommending engagement strategies. 
•	 Recommending strategies for assessing progress of the implementation of the plan. 
The ODP collected comments from the Working Group on the draft mission and vision statements, the 
draft strategic priorities, and the overall planning process. This feedback, along with input from the NIH 
Prevention Research Coordinating Committee, was used to develop revised materials that were then 
distributed to and reviewed by various stakeholders. The ODP Director met individually with Directors of 
NIH Institutes and Centers to get their input on the draft mission and vision statements. These discussions 
also focused on how the ODP could help advance Institute and Center efforts and how the NIH as a 
whole could strengthen the evidence base for prevention programs. Simultaneously, ODP staff worked 
with senior scientific staff at the NIH to gather additional insights on the mission and vision statements, 
as well as the strategic priorities for the Office. 
Information gathered from discussions shaped the development of revised mission and vision statements 
and revised strategic priorities. The updated material was posted online in a Request for Information (RFI) 
for broad input. The ODP sent invitations to various stakeholder communities inviting them to submit 
comments via the RFI. The ODP received responses from 79 organizations and individuals. 
The purpose of the RFI was to gather public input on specific objectives for each strategic priority as 
well as ideas about measures and timelines appropriate to those objectives. Respondents also were 
encouraged to comment on what the ODP could do to improve processes the NIH uses to solicit, review, 
and administer prevention-related research grants and cooperative agreements. 
To encourage continued participation by NIH staff, the ODP hosted a series of facilitated focus groups 
with NIH program and review staff designed to gather information on strategic priorities, measures, 
and timelines. As with the RFI, perspectives on how the NIH could improve the processes used to solicit, 
review, and administer research grants and cooperative agreements were gathered. 
The ODP integrated and analyzed the comments received through the RFI, focus groups, and other 
channels. ODP staff and volunteers from NIH Institutes and Centers worked in teams to synthesize the 
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feedback into measurable objectives, implementation timelines, and benchmarks for each of the strategic 
priorities. This information was compiled with the mission, vision, and other supporting materials to 
develop a draft strategic plan. The draft plan was submitted to the NIH leadership for review and revision. 
Finally, the draft plan was posted online for public comment and circulated to those involved in the 
formulation process. After revising the plan based on that input, the ODP resubmitted the plan to NIH 
leadership for final review and approval. 
APPENDIX C: ACRONYMS AND WEBSITES FOR
NIH INSTITUTES, CENTERS, AND OFFICES 
CSR Center for Scientific Review 
http://public.csr.nih.gov 
FIC Fogarty International Center 
http://www.fic.nih.gov 
NCATS National Center for Advancing Translational Sciences 
http://www.ncats.nih.gov 
NCCAM National Center for Complementary and Alternative Medicine 
http://nccam.nih.gov 
NCI National Cancer Institute 
http://www.cancer.gov 
NEI National Eye Institute 
http://www.nei.nih.gov
NHGRI National Human Genome Research Institute 
http://www.genome.gov
NHLBI National Heart, Lung, and Blood Institute 
http://www.nhlbi.nih.gov 
NIA National Institute on Aging 
http://www.nia.nih.gov
NIAAA National Institute on Alcohol Abuse and Alcoholism 
http://www.niaaa.nih.gov 
NIAID National Institute of Allergy and Infectious Diseases 
http://www.niaid.nih.gov 
NIAMS National Institute of Arthritis and Musculoskeletal and Skin Diseases 
http://www.niams.nih.gov 
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NIBIB National Institute of Biomedical Imaging and Bioengineering 
http://www.nibib.nih.gov 
NICHD Eunice Kennedy Shriver National Institute of Child Health and Human Development 
http://www.nichd.nih.gov 
NIDA National Institute on Drug Abuse 
http://www.drugabuse.gov 
NIDCD  National Institute on Deafness and Other Communication Disorders 
http://www.nidcd.nih.gov 
NIDCR National Institute of Dental and Craniofacial Research 
http://www.nidcr.nih.gov 
 
NIDDK  National Institute of Diabetes and Digestive and Kidney Diseases 
http://www.niddk.nih.gov 
NIEHS  National Institute of Environmental Health Sciences 
http://www.niehs.nih.gov 
NIGMS  National Institute of General Medical Sciences 
http://www.nigms.nih.gov 
NIMH  National Institute of Mental Health 
http://www.nimh.nih.gov 
NIMHD  National Institute on Minority Health and Health Disparities 
http://www.nimhd.nih.gov 
NINDS  
 
National Institute of Neurological Disorders and Stroke 
http://www.ninds.nih.gov 
NINR   National Institute of Nursing Research 
http://www.ninr.nih.gov 
NLM  National Library of Medicine 
http://www.nlm.nih.gov 
OAR  Office of AIDS Research 
http://www.oar.nih.gov 
OBSSR Office of Behavioral and Social Sciences Research 
http://obssr.od.nih.gov 
ODP Office of Disease Prevention 
http://prevention.nih.gov 
ODS  Office of Dietary Supplements 
http://ods.od.nih.gov 
ORWH Office of Research on Women’s Health   
http://orwh.od.nih.gov 
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APPENDIX D: ADDITIONAL WEBSITES
 
Agency for Healthcare Research and Quality (AHRQ) 
http://www.ahrq.gov 
Center for Tobacco Products (CTP), Food and Drug Administration (FDA) 
http://www.fda.gov/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/ 
AbouttheCenterforTobaccoProducts 
Centers for Disease Control and Prevention (CDC) 
http://www.cdc.gov 
Community Preventive Services Task Force (CPSTF) 
http://www.thecommunityguide.org/about/task-force-members.html 
Dietary Approaches to Stop Hypertension (DASH), National Heart, Lung, and Blood Institute
(NHLBI), NIH 
https://biolincc.nhlbi.nih.gov/studies/dash 
Food and Drug Administration (FDA) 
http://www.fda.gov 
Framingham Heart Study, National Heart, Lung, and Blood Institute (NHLBI), NIH 
http://www.framinghamheartstudy.org
Healthy People, U.S. Department of Health and Human Services (HHS)
http://www.healthypeople.gov/2020/
Hypertension Detection and Follow-up Program, National Heart, Lung, and Blood Institute
(NHLBI), NIH 
http://www.ncbi.nlm.nih.gov/pubmed/490882 
It’s a Noisy Planet. Protect Their Hearing®, National Institute on Deafness and Other
Communication Disorders (NIDCD), NIH 
http://www.noisyplanet.nidcd.nih.gov 
Kids’ Pages, National Institute of Environmental Health Sciences (NIEHS), NIH 
http://kids.niehs.nih.gov 
Medicine: Mind the Gap, Office of Disease Prevention (ODP), NIH 
http://prevention.nih.gov/mindthegap 
National High Blood Pressure Education Program, National Heart, Lung, and Blood Institute
(NHLBI), NIH 
http://www.nhlbi.nih.gov/about/nhbpep/ 
National Prevention Council
http://www.surgeongeneral.gov/initiatives/prevention/about/ 
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National Prevention Council Action Plan 
http://www.surgeongeneral.gov/initiatives/prevention/about/actionplan 
National Prevention Strategy
http://www.surgeongeneral.gov/initiatives/prevention/strategy/ 
NIDA for Teens, National Institute on Drug Abuse (NIDA), NIH 
http://teens.drugabuse.gov
Office of Disease Prevention (ODP) Co-Funded Projects, NIH 
http://prevention.nih.gov/cofund projects.aspx 
Office of Disease Prevention and Health Promotion (ODPHP), U.S. Department of Health and
Human Services (HHS) 
http://odphp.osophs.dhhs.gov 
Office of Portfolio Analysis (OPA), NIH 
http://dpcpsi.nih.gov/opa/ 
Pathways to Prevention (P2P), Office of Disease Prevention (ODP), NIH 
http://prevention.nih.gov/p2p/ 
Phenotypes and eXposures (PhenX) Toolkit, National Human Genome Research Institute
(NHGRI), NIH 
http://www.genome.gov/27541903/ 
Prevention Research Coordinating Committee (PRCC), Office of Disease Prevention (ODP), NIH 
http://prevention.nih.gov/prcc.aspx 
Research, Condition, and Disease Categorization (RCDC), NIH 
http://report.nih.gov/rcdc/ 
Robert S. Gordon, Jr. Lecture in Epidemiology, Office of Disease Prevention (ODP), NIH 
http://prevention.nih.gov/gordon.aspx 
Smokefree Teen, National Cancer Institute (NCI), NIH 
http://teen.smokefree.gov 
Tobacco Regulatory Science Program (TRSP), Office of Disease Prevention (ODP), NIH 
http://prevention.nih.gov/tobacco/ 
U.S. Department of Health and Human Services (HHS) 
http://www.hhs.gov 
U.S. Preventive Services Task Force (USPSTF) 
http://www.ahrq.gov/professionals/clinicians-providers/guidelines-recommendations/uspstf/ 
We Can! (Ways to Enhance Children’s Activity & Nutrition)®, National Heart, Lung, and Blood
Institute (NHLBI), NIH 
http://www.nhlbi.nih.gov/health/public/heart/obesity/wecan/ 
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